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Background and purpose: Hypoxia is a common feature of solid tumors associated with therapy resistance, increased
malignancy and poor prognosis. Several approaches have been developed with the hope of identifying patients harboring
hypoxic tumors including the use of microarray based gene signatures. However, studies to date have largely ignored the
strong time dependency of hypoxia-regulated gene expression. We hypothesized that use of time-dependent patterns of
gene expression during hypoxia would enable development of superior prognostic expression signatures.
Materials and methods: Using published data from the microarray study of Chi et al., we extracted gene signatures
correlating with induction during either early or late hypoxic exposure. Gene signatures were derived from in vitro
exposed human mammary epithelial cell line (HMEC) under 0% or 2% oxygen. Gene signatures correlating with early and
late up-regulation were tested by means of Kaplan–Meier survival, univariate, and multivariate analysis on a patient data
set with primary breast cancer treated conventionally (surgery plus on indication radiotherapy and systemic therapy).
Results: We found that the two early hypoxia gene signatures extracted from 0% and 2% hypoxia showed significant
prognostic power (log-rank test: p = 0.004 at 0%, p = 0.034 at 2%) in contrast to the late hypoxia signatures. Both early
gene signatures were linked to the insulin pathway. From the multivariate Cox-regression analysis, the early hypoxia
signature (p = 0.254) was found to be the 4th best prognostic factor after lymph node status (p = 0.002), tumor size
(p = 0.016) and Elston grade (p = 0.111). On this data set it indeed provided more information than ER status or p53
status.
Conclusions: The hypoxic stress elicits a wide panel of temporal responses corresponding to different biological
pathways. Early hypoxia signatures were shown to have a significant prognostic power. These data suggest that gene
signatures identified from in vitro experiments could contribute to individualized medicine.
c 2007 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 83 (2007) 374–382.
Keywords: Gene Expression Signature; Molecular medicine; Time series; Hypoxia; InsulinMaintenance of physiological oxygen concentrations is a
highly dynamic process vital to many aspects of cell biology.
Lack of oxygen (hypoxia) is a frequently encountered situa-
tion in solid tumors and is associated with increased radio-
therapy and chemotherapy resistance, malignancy and
poor prognosis [2,8,18,19,22,23]. Hypoxia is known to be
highly heterogeneous within tumors in terms of its spatial
distribution, severity and kinetics. Hypoxia arises through
different mechanisms associated primarily with limits in
oxygen diffusion (chronic hypoxia) and blood perfusion
(acute hypoxia). In addition, hypoxia regulates several dif-0167-8140/$ - see front matter c 2007 Elsevier Ireland Ltd. All rights referent cellular pathways that have unique activation
kinetics and sensitivity to oxygen concentration. As a
consequence, hypoxia-regulated gene expression is complex
and displays large temporal characteristics.
With DNA micro-arrays, it is now possible to monitor the
expression of several tens of thousands of genes at once. In
oncology, this ability is exploited to extract lists of genes (or
gene signatures) rather than to rely on a few clinical vari-
ables for diagnosis [5,14] or prognosis. For the latter, these
gene sets include those derived from clinical data, in which
correlation with a supervised classifier identifies the clinicalserved. doi:10.1016/j.radonc.2007.05.002
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cently, in vitro derived gene sets have been described con-
taining genes associated with a particular phenotype
hypothesized to be clinically important [1,3,4,9]. This al-
lows an unbiased test of such a hypothesis, by applying
the in vitro derived signature to a separate patient micro-
array study. This latter type of study recently demonstrated
that a gene signature for hypoxia could act as a prognostic
factor in a range of different tumor types. In this latter
study, Chi et al. [4] also measured the temporal gene
expression programs under hypoxia for several primary cell
lines in vitro. We hypothesized that because of the large
dependency of hypoxic gene expression on time, this data
set might be used to extract hypoxic gene signatures that
reflect differences between slow and fast hypoxia kinetic
responses and their contribution to prognosis. We therefore
isolated gene sets correlating with early induction during
hypoxia and compared these with genes up-regulated after
long hypoxia. Our data indicate that the early hypoxia gene
signatures may be useful prognostic tools.Materials and methods
Data set
The starting material was the data set provided by the
study of Chi et al., which represents, to our knowledge,
the largest set of time series under hypoxia with 2.4 million
of gene expression measurements. Four normal cell lines
were used: human coronary artery endothelial cells (ECs),
smooth muscle cells (SMCs), human mammary epithelial
cells (HMECs), and renal proximal tubule epithelial cells
(RPTECs 1 and 2) under two oxygen concentrations (less
than 0.02% and 2%). Using cDNA microarrays of 42,000
reporters, gene expression was monitored under hypoxia
resulting in 10 time series with at most six time points for
each. After they filtered for noise and intensity, the time
series of the remaining 4333 reporters was plotted as
Fig. 1a [4]. This data set was downloaded from http://
microarray-pubs.stanford.edu/hypoxia/index.htm. SM and
HMEC both had the longest time series, i.e. six time points:
0, 1, 3, 6, 12 and 24 h of hypoxia, each for two oxygen con-
centrations (less than 0.02% and 2%). The absence of early
time points did not allow us to include the other cell lines.
As also found by Chi et al., it was not possible to clearly de-
fine differential expression for the SM cell line due to a low
range of expression between up- and down-regulation. Our
analysis thus focused only on the two time series provided
for the HMEC cell line: one with an oxygen concentration
less than 0.02% (HMEC0), the other under 2% (HMEC2).
A batch query was made with SOURCE (http://smd.stan-
ford.edu/cgi-bin/source/sourceSearch) to translate the
4333 CLONEIDs into UniGenes (last accession: February
2007, Build 199). A reporter (probe) was removed if at least
one of the following criteria was met: no UniGene identifier
was found (328 such reporters); one reporter corresponded
to multiple UniGene identifiers (257 such reporters); the
Gene Symbol was corresponding to mitochondria (28 such
reporters); the UniGene was not for Human (1 such
reporter).For each time series independently, the remaining 3719
reporters were further filtered out if at least one time point
was missing. For HMEC0 this resulted in a time series of 1196
reporters represented by 1082 unique genes. For the HMEC2
series, it consisted of 1047 reporters representing 955
unique genes.Gene expression profiling
Extraction of genes with an up-regulation in early time
points was assessed in a supervised way (Fig. 1a). A Pearson
correlation was selected as a similarity distance to select
profiles based on their time-dependent shape but regardless
of their magnitude changes (i.e. an early low or an early
high up-regulation is found to be equivalent in these condi-
tions). A curve of interest representing the pattern of gene
expression as a function of time was user-defined as a se-
quence of zeros and ones. The time points 1, 3 and 6 h were
considered early time points in the hypoxia response
whereas 12 and 24 h were reckoned late time points. The
curve of interest for selecting genes with an early up-regu-
lation that return back to basal level for late time points
was thus set to be 0-111-00. This template was used to se-
lect each gene whose temporal profile was similar to this
a priori determined pattern of expression. A filtering step
was included to require at least a 2-fold induction (with re-
spect to expression under control condition). This proce-
dure was run for each cell line independently (Fig. 1b). A
correlation coefficient of 0.6 was selected to provide gene
lists of manageable sizes.
We compared the early hypoxia signature (curve of inter-
est: 0-111-00 for control–early–late time points) to a late
hypoxia pattern with a curve of interest being: 0-000-11,
meaning that gene expression had to be constant and equal
to control value during the three early time points, then up-
regulated at 12 and 24 h of hypoxia (Fig. 1c). For each time
series, three types of gene signatures were derived: early
hypoxia, late hypoxia (matching the correlation coefficient
(long version), late hypoxia matching the number of report-
ers (short version)).Statistical analyses
The gene expression based signatures extracted in vitro
were evaluated in vivo on a large cancer study providing
microarray data (downloaded from http://www.ncbi.nlm.
nih.gov/projects/geo/, Accession No. GSE3494). Clinical
annotations for its 251 patients (a subset of the Uppsala co-
hort) with primary breast cancer (Table 1) treated with sur-
gery plus on indication adjuvant radiotherapy and systemic
therapy [13,16]. Expression data were log-transformed and
multiple reporters for the same gene symbol were aver-
aged. Depending on the overall expression of the genes se-
lected in the signature, a patient was assigned to either the
high expression or the low expression group. Outcome in the
two groups was analyzed and compared by the Kaplan–Me-
ier method. Log-rank tests were computed to assess survival
differences between the two groups. Univariate and multi-
variate Cox regression analyses were run with SPSS (SPSS,
Chicago, IL.) including all the clinical variables and the early
signature under 0%. A machine learning approach was also
used to assess the impact of the early signature. It was com-
Fig. 1. Log base 2 values of induction (red) and repression (green) with respect to control level (in black, missing data in (a) also): (a) Pipeline
of the analysis: from the microarray data from the Chi study. Temporal filters were used to profile: early and late gene signatures for HMEC cell
line under 0% and 2% of oxygen concentration. (b) Log induction of the 80 reporters (0%) and 36 reporters (2%) matching the curve of interest
for the early hypoxia signature. The UniGene overlap is included. (c) Log induction of the late signatures. For each early signature, two late
versions were derived: one matching the correlation coefficient, the other with a similar size. Venn diagrams are used to compare their
content.
376 Early hypoxia gene signatureposed of (1) a feature selection (by leave-one-out cross-val-
idation) followed by (2) a validation stage consisting of a
bootstrapping procedure (resampling with replacement)where a randomly picked 70% of the data was used for train-
ing and the remaining 30% of the data was used for testing.
This procedure was repeated 100 times and the means and
Table 1
Clinical information for the 251 patients composing the valida-
tion set
Characteristic
No. of patients 251
Age (years) 62.1 ± 13.9
Tumor stage – No. of patients (%)
Stage I 67 (26.7)
Stage II 128 (51.0)
Stage III 54 (21.5)
Tumor size (mm) 22.4 ± 12.5
ER status – No. of patients (%)
Positive 213 (84.9)
Negative 34 (13.5)
Lymph node status – No. of patients (%)
Positive 84 (33.5)
Negative 158 (62.9)
Progesterone receptor status – No. of patients (%)
Positive 190 (75.7)
Negative 61 (24.3)
p53 status – No. of patients (%)
Positive 58 (23.1)
Negative 193 (76.9)
R. Seigneuric et al. / Radiotherapy and Oncology 83 (2007) 374–382 377standard deviations of the results were reported. Also, mul-
tivariate models representing all the possible variable com-
binations (28  1 = 255) were tested and the top five
performing models were retained.Results
Correlating genes with a predefined pattern of interest
was used to derive early hypoxia gene signatures from the
HMEC cell lines under 0% and 2% oxygen. The genes reaching
a correlation with the required temporal profile greater
than 0.6 and a 2-fold induction or more were selected
(Table 2). Results from log-rank tests on the Miller data
set are reported in Table 3.
HMEC0%
This number of reporters correlating with early induction
(early hypoxia gene signature) following exposure to 0% oxy-
gen was equal to 80 (79 unique UniGenes). For the same level
of correlation, 241 reporters (210 unique UniGenes) were
found for the late hypoxic signature (late long hypoxic signa-
ture). For comparison, we also increased the required corre-
lation to reduce the number of reporters to match a size
similar to the early signature. This late short hypoxic signa-
ture contained 74 reporters (70 unique UniGenes). Of these
three signatures, only the early hypoxia signature was signif-
icant on the breast cancer data set (p = 0.004 for difference
in survival). Surprisingly, the late signatures were not signif-
icant and showed no evidence of splitting the patients into
different prognostic groups (p = 0.118 and 0.110 for the long
and short versions, respectively) (Fig. 2).
HMEC2%
Under 2%, the number of selected reporters was smaller
than under 0%. The early gene signature contained 36reporters (36 unique UniGenes) exhibiting an up-regulation
within the first hours (1–3–6 h) following hypoxia exposure.
The late long hypoxia signature derived with a correlation
threshold of 0.6 was made of 169 reporters (147 unique
UniGenes). For the short version, the correlation threshold
was raised to yield a size comparable to the early one. It
was composed of 34 reporters (32 UniGenes). Similar to
the results under 0%, the early hypoxia signature was the
only significant signature (p = 0.034) while the long and
short versions of the late hypoxia signature were not (p-va-
lue of 0.919 and 0.842, respectively).
Combination of signatures (0% and 2%)
Time series without missing data HMEC under 0% (1082
UniGenes) and 2% (955 UniGenes) had a large overlap: 793
UniGenes. Comparing the 2 early signatures revealed a small
overlap (15 UniGenes). This core HMEC response was also
tested and had a p-value of 0.005 (log-rank test). The over-
lap between the two long late signatures showed an overlap
of 93 UniGenes. This core signature for late response was
tested and found to be not significant (p = 0.240) on the
breast cancer data set.
In order to link the genes from the early signatures to bio-
logical functions, Gene Ontologies analyses were run with
Ingenuity Pathways Analysis (Ingenuity Systems, Redwood
City, CA). The results provided for the top functions are
shown in Table 4. For both early signatures, only two top
functions were found. The genes selected for enrichment
(‘focus genes’) are listed and mainly involved in prolifera-
tion, cell cycle and cancer. For the core early response
(intersection of 0% and 2%), the top function was related
to amino acid metabolism.
Prognostic power of the early signature (HMEC0)
A univariate Cox-regression analysis was run for the early
signature (HMEC0) on the Miller data set with all the vari-
ables provided and the early hypoxia score. The signature
score was found to be significant (p-value <0.05), while
PgR status, ER status and age were not.
From the multivariate analysis (with a stepbackward fea-
ture selection procedure), the early hypoxia signature
(p = 0.254) was found to be the 4th best prognostic factor
after lymph node status (p = 0.002), tumor size (p = 0.016)
and Elston grade (p = 0.111). On this data set, it indeed pro-
vided more information than ER status or p53 status (both
individually and when combined with other variables) for
instance.
A multivariate analysis with a machine learning-based
feature selection approach was also run. Providing all the
variables to the algorithm (but age and the early signature
score) gave an Area Under the Curve (AUC) of 62.3 with a
standard deviation (std) of 0.07. Repeating the same analy-
sis but adding age only gave an AUC of 62.2 with a std of
0.07. When age and the signature score were added to-
gether, the AUC was 62.5 (std of 0.07). When only the signa-
ture score was added, the AUC was 66.1 (std of 0.06). From
the hundred runs computed for each analysis, a t-test was
performed between the six variables and the signature score
versus the six variables and the age. A p-value of 4.8e6
suggested that age is less effective than the signature score
on this data set.
Table 2
Content of the early and late hypoxia gene signatures in terms of UniGene cluster IDs: late hypoxia signatures are represented by their short
versions only
Early 0% Late 0% short Early 2%
UniGene Symbol Corr. Max UniGene Symbol Corr. Max UniGene Symbol Corr. Max
Hs.592692 0.95 1.59 Hs.102267 LOX 1.00 1.26 Hs.72550 HMMR 0.90 2.39
Hs.633514 TIMP2 0.92 3.49 Hs.435051 CDKN2D 1.00 1.16 Hs.528299 HTATIP 0.90 1.84
Hs.127126 CPEB4 0.91 1.80 Hs.520819 INSIG1 0.99 2.18 Hs.5 10078 SGK 0.86 1.58
Hs.334587 RBPMS 0.90 1.35 Hs.380906 MYADM 0.98 1.56 Hs.6 33514 TIMP2 0.86 3.83
Hs.648626 0.89 1.09 Hs.102267 LOX 0.98 2.38 Hs.6 02706 LOC6 45591 0.86 1.63
Hs.646346 GAS6 0.87 1.65 Hs.523012 DDIT4 0.98 1.69 Hs.642877 MALAT1 0.85 2.46
Hs.584803 ST3GAL1 0.87 1.45 Hs.465870 KEAP1 0.97 1.42 Hs.5 93232 0.84 3.25
Hs.567495 TRNT1 0.85 1.80 Hs.649390 0.97 1.20 Hs.5 96783 0.82 1.59
Hs.651126 DUSP3 0.85 1.50 Hs.173381 DPYSL2 0.97 2.70 Hs.441113 MAGEA6 0.80 1.06
Hs.478746 CENTB2 0.84 2.60 Hs.287659 STRBP 0.97 2.70 Hs.149983 PEX14 0.79 4.42
Hs.72550 HMMR 0.83 1.81 Hs.131433 ADAMTS13 0.97 3.65 Hs.94542 ALKBH1 0.79 1.18
Hs.154276 BACH1 0.83 1.18 Hs.443976 CEP250 0.97 1.52 Hs.154276 BACH1 0.77 2.12
Hs.233568 HIST1H2AL 0.82 2.15 Hs.235782 SLCO4A1 0.96 2.24 Hs.1 89772 CCT2 0.77 4.09
Hs.106861 NSD1 0.81 1.51 Hs.405662 CRABP2 0.96 1.33 Hs.112432 AMH 0.76 2.54
Hs.414418 BET1L 0.80 3.41 Hs.34871 ZFHX1B 0.96 2.58 Hs.643599 PAPPA 0.74 1.51
Hs.593565 0.80 4.08 Hs.269722 TCBA1 0.96 1.65 Hs.1 26774 DTL 0.74 1.76
Hs.235116 GRK6 0.79 1.94 Hs.540696 SLC6A8 0.96 3.26 Hs.1 46406 NIT1 0.73 2.04
Hs.554791 TP53111 0.79 1.65 Hs.644065 TSC22D2 0.96 1.43 Hs.463838 LOC440459 0.73 1.25
Hs.226780 OSTM1 0.79 1.86 Hs.129003 0.95 2.49 Hs.5 23847 IFI6 0.72 4.45
Hs.525549 BTBD7 0.79 2.68 Hs.502116 NAV2 0.95 2.02 Hs.4 6700 ING1 0.72 1.08
Hs.536158 PARG 0.79 2.83 Hs.511915 ENO2 0.95 4.10 Hs.55131 C3orf23 0.71 1.21
Hs.436489 ATP5S 0.79 1.12 Hs.530381 PIM3 0.95 2.03 Hs.558396 SCD 0.70 1.64
Hs.643279 EIF4EBP2 0.79 2.96 Hs.530381 PIM3 0.95 2.03 Hs.148907 SLC5A12 0.70 4.49
Hs.189772 CCT2 0.77 3.24 Hs.379821 FAM83A 0.95 1.36 Hs.643920 C1GALT1C1 0.69 2.17
Hs.78977 PCSK1 0.76 2.18 Hs.96996 HNRPAO 0.95 2.50 Hs.1 60556 ACACA 0.67 1.78
Hs.155983 JMJD2A 0.76 2.03 Hs.26010 PFKP 0.94 1.56 Hs.5 62083 ICMT 0.66 2.27
Hs.612872 TTLL5 0.76 2.23 Hs.75093 PLOD1 0.94 2.01 Hs.515383 LOC644242 0.66 4.93
Hs.435933 PHF10 0.76 1.55 Hs.525704 JUN 0.93 2.15 Hs.5 13430 CDR2 0.65 2.10
Hs.489603 ATXN7L1 0.76 3.60 Hs.446240 PRKCBP1 0.93 1.44 Hs.155983 JMJD2A 0.63 2.71
Hs.128959 PCF11 0.75 3.40 Hs.89387 CASC2 0.93 1.96 Hs.590575 GRM3 0.62 3.65
Hs.335205 SSH2 0.74 2.84 Hs.288232 SERINC5 0.93 1.03 Hs.632226 ITGB4 0.62 1.49
Hs.146406 NIT1 0.74 1.81 Hs.533887 SMEK1 0.93 1.39 Hs.1 65607 FLJ25416 0.62 1.02
Hs.596783 0.73 1.14 Hs.78771 PGK1 0.93 2.41 Hs.514033 SPAG5 0.61 1.92
Hs.512973 PTPLAD1 0.73 1.71 Hs.108106 UHRF1 0.93 1.46 Hs.6 32447 WDR42A 0.61 1.87
Hs.461030 GFOD2 0.73 1.99 Hs.644649 0.93 3.49 Hs.8 9603 MUC1 0.60 2.11
Hs.149983 PEX14 0.73 4.49 Hs.445402 PCTK3 0.93 3.23 Hs.4 34961 ATXN1 0.60 2.34
Hs.1310.4 ACOX1 0.73 2.21 Hs.535297 ARID5B 0.93 2.73
Hs.292524 CCNH 0.72 3.27 Hs.515032 MKNK2 0.92 2.76
Hs.283749 RNASE4 0.71 1.74 Hs.422113 ZNF511 0.92 1.80 Late 2% short
Hs.287362 TLE3 0.71 4.38 Hs.133350 CNOT2 0.92 2.65 UniGene Symbol Corr. Max
Hs.492203 TERT 0.71 1.20 Hs.146688 PTGES 0.92 1.15 Hs.446017 WSB1 1.00 1.77
Hs.250693 ZNF117 0.71 1.04 Hs.460355 PRKCB1 0.92 2.79 Hs.3 70365 HK1 1.00 1.13
Hs.593232 0.70 3.15 Hs.369520 SYTL2 0.92 4.32 Hs.5 20819 INSIG 1 0.97 1.51
Hs.590575 GRM3 0.70 3.26 Hs.647120 MLL3 0.92 4.44 Hs.405662 CRABP2 0.96 2.02
Hs.428214 MAML2 0.70 3.13 Hs.517145 ENO1 0.92 1.62 Hs.173705 LOC401152 0.94 2.24
Hs.523847 IFI6 0.70 4.68 Hs.533782 KRT8 0.91 1.83 Hs.644649 0.94 2.91
Hs.533712 RBM4 0.70 2.29 Hs.21691 GPR75 0.91 1.55 Hs.446017 WSB1 0.94 1.32
Hs.44067 C12orf53 0.69 1.69 Hs.458513 PPP1R3B 0.91 2.57 Hs.511915 ENO2 0.94 3.18
Hs.647072 PRKAG2 0.68 1.59 Hs.643452 DGCR8 0.91 2.82 Hs.4 74935 SEMA4B 0.94 2.40
Hs.606472 0.68 3.93 Hs.591443 RAVER2 0.91 1.14 Hs.497822 DUSP10 0.94 2.06
Hs.149032 PIK3R4 0.68 1.21 Hs.433146 SLC6A10P 0.91 3.62 Hs.3 35614 SEC14L2 0.93 2.59
Hs.436705 KIAA1219 0.68 2.10 Hs.429879 EHHADH 0.91 4.21 Hs.102267 LOX 0.93 2.47
Hs.631539 RAB4B 0.67 2.42 HS.9613 ANGPTL4 0.91 4.95 Hs.287659 STRBP 0.93 1.78
Hs.529353 ACSS1 0.67 2.55 Hs.494529 FANCC 0.91 1.94 Hs.5 02116 NAV2 0.91 1.82
Hs.592020 IGF1R 0.67 4.02 Hs.523012 DDIT4 0.91 2.14 Hs.581021 SIR PA 0.91 1.08
Hs.642938 IGFBP1 0.67 1.63 Hs.97858 KIF1B 0.90 2.55 Hs.403933 FBXO32 0.91 2.85
Hs.631930 LOC64645 0 0.67 2.42 Hs.581355 EIF4E3 0.90 3.84 Hs.5 00047 P4HA1 0.91 2.97
Hs.148907 SLC5A12 0.66 5.14 Hs.530904 CSRP2 0.90 1.32 Hs.540696 SLC6A8 0.90 2.43
Hs.160556 ACACA 0.65 1.63 Hs.159430 FNDC3B 0.90 1.73 Hs.2795 LDHA 0.89 1.38
Hs.126891 IL22RA2 0.64 1.63 Hs.435667 USP34 0.90 1.93 Hs.9613 ANGPTL4 0.89 3.64
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Table 2 (continued)
Early 0% Late 0% short Late 2% short
UniGene Symbol Corr. Max UniGene Symbol Corr. Max UniGene Symbol Corr. Max
Hs.124011 0.64 1.70 Hs.505172 LOC645619 0.90 1.93 Hs.535297 ARID5B 0.89 2.28
Hs.524828 ZNF664 0.64 3.12 Hs.446017 WSB1 0.90 2.09 Hs.173381 DPYSL2 0.89 2.19
Hs.4779 GATAD2B 0.64 2.28 Hs.470633 PDK1 0.89 2.22 Hs.429879 EHHADH 0.89 2.88
Hs.612872 TTLL5 0.63 1.63 Hs.501023 MXI1 0.89 4.06 Hs.4 25144 MTMR11 0.89 1.74
Hs.233240 COL6A3 0.63 1.19 Hs.501023 MXI1 0.89 1.92 Hs.98643 RAP2B 0.89 1.44
Hs.445030 RHOBTB3 0.63 3.76 Hs.46423 HIST1H4C 0.89 1.75 Hs.34871 ZFHX1B 0.88 2.08
Hs.460 ATF3 0.63 1.79 Hs.433146 SLC6A10P 0.89 3.61 Hs.591140 FOXK2 0.88 2.09
Hs.112432 AMH 0.63 2.24 Hs.591849 C8orf4 0.89 2.18 Hs.581355 EIF4E3 0.87 2.15
Hs.544738 LY86 0.63 3.32 Hs.159195 DOCK1 0.89 3.02 Hs.1 55247 ALDOC 0.87 1.38
Hs.530941 C12orf30 0.63 3.66 Hs.372914 NDRG1 0.89 5.68 Hs.501023 MXI1 0.87 2.77
Hs.180903 NCAPH2 0.63 1.81 Hs.80 04 KALRN 0.89 2.67 Hs.5 36075 0.87 1.41
Hs.76364 AIF1 0.62 3.06 Hs.523789 TncRNA 0.89 2.14 Hs.1 02267 LOX 0.86 1.79
Hs.43627 SOX12 0.62 6.59 Hs.634882 ARL6IP1 0.88 2.39 Hs.135213 HSD17B12 0.86 3.51
Hs.643599 PAPPA 0.62 1.96 Hs.585433 KIRREL 0.88 2.60 Hs.1 32342 LPIN2 0.86 1.87
Hs.125038 FAM92A1 0.61 1.82
Hs.131342 CCL26 0.61 2.59
Hs.512767 DKFZP761H1 0.61 2.67
Hs.631974 LOC728488 0.60 1.31
Hs.112873 IGSF11 0.60 1.65
Hs.6217 0.60 1.93
Lists are sorted by descending correlation coefficient with the curve of interest. Maximum induction (in log scale) is also provided.
Table 3
Validation of the early hypoxia gene signatures: statistical differences between Kaplan–Meier survival curves were assessed by computed
mean p-values obtained from log-rank tests at 5 and 10 years
Oxygen concentration (%) Hypoxia type Corr. coeff. No. of reporters No. of unique UniGenes p-value
0 Early 0.6 80 79 0.004
0 Late 0.6 241 210 0.118
0 Late 0.88 74 70 0.110
2 Early 0.6 36 36 0.034
2 Late 0.6 169 147 0.919
2 Late 0.86 34 32 0.842
0 & 2 Chi et al. n.a. 253 171 0.300
0 & 2 Early 0.6 15 15 0.005
0 & 2 Late 0.6 93 93 0.240
For each signature, its type, correlation coefficient (not applicable for the Chi study), number of reporters and number of unique UniGene
cluster IDs are also given.
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combinations were considered for training a multivariate
model, four out of the top five performing combinations in-
cluded the signature score.Discussion
Early hypoxia
In this paper, we focus on the impact of the early re-
sponse to hypoxia which with the exception of a few studies
(e.g. [12]) is rarely investigated by means of microarrays.
Due to potential differences arising for different oxygen
concentrations, the two time series were treated indepen-
dently. Both early hypoxia signatures were significant
(p < 0.01 at 0%; p < 0.05 at 2%) whereas none of the late sig-
natures were. A signature of the 15 common UniGenes (13
symbols) found in the two early signatures was also tested
and found to be significant (p = 0.005).Ingenuity Pathways Analysis identified genes within this
list including ACACA, AMH, BACH1, CCT2 (related to
growth and apoptosis) and IFI6 in Cancer, Tumor Morphol-
ogy, Amino Acid Metabolism (Table 4). Focusing on the
early signature at 0% (p = 0.004) with Ingenuity Pathways
Analysis revealed a significant contribution of IGF1R (from
the canonical insulin pathway), TERT (Telomerase reverse
transcriptase), AMH, COL6A3, and ACACA in apoptosis,
growth and proliferation. CCNH (from the estrogen recep-
tor pathway) as well as transcription factors ATF3 and
BACH1 were also identified. The early signature may re-
flect activation of the Unfolded Protein Response (ATF3
for instance), which is known to be activated rapidly in
response to hypoxia. Cross-talk between oxygen and glu-
cose metabolism via HIF1 have been reported [11,15] as
well as the protective role of IGF1 against cell degenera-
tion in animal models after stroke such as hypoxia–ische-
mia [17].
Fig. 2. Kaplan–Meier survival curves for disease specific survival (follow-up to 12 years) and p-values for the different gene signatures. The
group with a low (high) expression of the signature is plotted in blue (red). (a) Chi signature, (b) early hypoxia (under 0% or 2%), and (c) late
signatures.
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The late signatures (0% and 2%) were found to be very
similar to the Chi signature, with an overlap for each one
greater than 40% (and up to 70% with their short versions).
The biological theme of the late signatures is also typicalof a hypoxic response [6], with genes encoding proteins in-
volved in the hypoxia pathway and angiogenesis (ANGPTL4,
CA9, DDIT4, EGLN3, EGFR, HK2, HIG2, LOX), cell prolifera-
tion and apoptosis (BNIP3L, NDRG1, MXI1), glucose transport
(many members of the solute carrier family including
Table 4
Gene Ontology provided by Ingenuity for the early signatures
Oxygen concentration Top functions Score Focus genes Gene symbols





27 14 AIF1, ATF3, BACH1, CCL26, COL6A3, GATAD2B,




25 13 ACACA, ACOX1, ACSS1, AMH, CCNH, CCT2,




27 12 ACACA, AMH, BACH1, CDR2, HTATIP, IFI6, ING1,





9 5 CCT2, GRM3, HMMR, ICMT, MUC1
0% & 2% Cancer,
tumor morphology,
amino acid metabolism
11 5 ACACA, AMH, BACH1, CCT2, IFI6
For each one, the top two functions which correspond to the highest scores are shown, as well as the genes contributing to the score. The
top function of early genes overlapping between 0% and 2% are also given.
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(ADM). Similar to the four derived late hypoxia signatures,
the Chi signature was found to be not significant in this data
set. This suggests that late signatures are very similar to the
Chi signature not only in gene content but also in terms of
prognostic power.
Unsupervised and supervised hypoxia signatures
Cluster analysis [7] is a commonly used technique [3,10]
to assess shared functions and common regulation in an
unbiased way since the algorithm does not require user-de-
fined (i.e. supervised) assumptions on the numbers or type
of clusters to be found. The underlying idea is that genes
with a similar expression pattern are likely to also be in-
volved in the same regulatory process (referred to as ‘Guilt
by association’). This approach was used by Chi et al., to
group temporal gene expression under hypoxia. From HMECs
and RPTECs, one cluster of global up-regulated genes was
then selected after visual inspection to form the ‘epithelial
cell hypoxia genes’ or so-called Chi signature. The gene con-
tent of the early hypoxia signatures had virtually no overlap
with the Chi signature: 2 UniGenes at 0% (Hs.149032, PIK3R4
and Hs.283749, RNASE4), and only 1 at 2% (Hs.94542,
ALKBH1). This suggested that the early signatures are very
different from the Chi signature.
Although external changes in milieu (e.g. hypoxia) are
sensed very rapidly by the cell, large changes at the tran-
scriptional level occur mostly after several hours. Our super-
vised method was developed to extract a handful of genes
involved in the early hypoxic response (i.e. from 1 to 6 h of
hypoxia). Overlap was seldom found between the early and
the late signatures: only one UniGene at 0% (Hs.106861,
NSD1), and none under 2%. It shows that early signatures
are different from late signatures (including the Chi signa-
ture) both in gene content and in patients they select.
All early hypoxia signatures whether extracted under 0%,
2% or their overlap were found significant on the Miller dataset. Focusing on the former for multivariate analyses con-
firmed its prognostic power. At this moment it is unclear
why the early hypoxic signatures provide superior prognostic
information in this data set. It may reflect differential acti-
vation of hypoxia response pathways, but may also select
patients with more aggressive tumors (more metastasis),
resistance to treatment or both. We are currently investi-
gating additional methods to validate our early gene signa-
tures such as in vitro experiments with RNAi to selectively
down-regulate gene products (e.g. TERT or IGF1R) or by fur-
ther testing the gene signature on independent clinical data
sets with distinct clinical features. This retrospective study
could be useful in the field of radiotherapy and oncology by
suggesting the need for a prospective clinical study provid-
ing clinical data together with microarray data and an inde-
pendent measure of hypoxia (by Eppendorf electrodes or
immunochemistry staining for instance).Conclusions
This analysis shows that, consistent with our hypothesis,
the early and late hypoxia responses are very different at
the transcription level. In a relatively old cohort of patients
with primary breast cancer treated by locoregional therapy
and systemic adjuvant therapy, it was shown that early hy-
poxia signatures, but not late hypoxia responses, could cor-
relate with survival differences. It suggests that gene
signatures can provide a means to select patients for indi-
vidualized therapy.Acknowledgements
We acknowledge financial support from Siemens (to R.S. and
M.H.W.S.), the Dutch Science Organization (ZonMW-NWO Top Grant
912-03-047 to B.W.), the Dutch Cancer Society (KWF Grant UM 2003-
382 Early hypoxia gene signature2821 to B.W.), and the EU 6th framework program (Euroxy program
to B.W.).
* Corresponding author. Dr. Philippe Lambin, Department of
Radiation Oncology (MAASTRO), GROW Research Institute, Univer-
sity Hospital Maastricht, Dr. Tanslaan 12, 6229 ET Maastricht, The
Netherlands. E-mail address: philippe.lambin@maastro.nl
Received 27 March 2007; received in revised form 1 May 2007;
accepted 1 May 2007; Available online 25 May 2007
References
[1] Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with
therapeutic opportunities. Nat Rev Cancer 2006;6:735–41.
[2] Bussink J, Kaanders JH, van der Kogel AJ. Microenvironmental
transformations by VEGF- and EGF-receptor inhibition and
potential implications for responsiveness to radiotherapy.
Radiother Oncol 2007;82:10–7.
[3] Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression
signature of fibroblast serum response predicts human cancer
progression: similarities between tumors and wounds. PLoS
Biol 2004;2:E7.
[4] Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in
response to hypoxia: cell type specificity and prognostic
significance in human cancers. PLoS Med 2006;3:e47.
[5] Chung CH, Bernard PS, Perou CM. Molecular portraits and the
family tree of cancer. Nat Genet 2002;32:533–40.
[6] Denko NC, Fontana LA, Hudson KM, et al. Investigating
hypoxic tumor physiology through gene expression patterns.
Oncogene 2003;22:5907–14.
[7] Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis
and display of genome-wide expression patterns. Proc Natl
Acad Sci USA 1998;95:14863–8.
[8] Eriksen JG, Horsman MR. Tumour hypoxia – a characteristic
feature with a complex molecular background. Radiother
Oncol 2006;81:119–21.
[9] Huang ES, Black EP, Dressman H, West M, Nevins JR. Gene
expression phenotypes of oncogenic signaling pathways. Cell
Cycle 2003;2:415–7.
[10] Iyer VR, Eisen MB, Ross DT, et al. The transcriptional program
in the response of human fibroblasts to serum. Science
1999;283:83–7.[11] Kietzmann T, Krones-Herzig A, Jungermann K. Signaling cross-
talk between hypoxia and glucose via hypoxia-inducible factor
1 and glucose response elements. Biochem Pharmacol
2002;64:903–11.
[12] Koritzinsky M, Seigneuric R, Magagnin MG, van den Beucken T,
Lambin P, Wouters BG. The hypoxic proteome is influenced by
gene-specific changes in mRNA translation. Radiother Oncol
2005;76:177–86.
[13] Miller LD, Smeds J, George J, et al. An expression signature
for p53 status in human breast cancer predicts mutation
status, transcriptional effects, and patient survival. Proc Natl
Acad Sci USA 2005;102:13550–5.
[14] Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer
diagnosis using tumor gene expression signatures. Proc Natl
Acad Sci USA 2001;98:15149–54.
[15] Riedemann J, Macaulay VM. IGF1R signalling and its inhibition.
Endocr Relat Cancer 2006;13:S33–43.
[16] Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast
cancer: prognostic value of complementary DNA sequencing
versus immunohistochemistry.JNatlCancer Inst 1996;88:173–82.
[17] Smith PF. Neuroprotection against hypoxia-ischemia by insu-
lin-like growth factor-I (IGF-I). IDrugs 2003;6:1173–7.
[18] Sorensen BS, Hao J, Overgaard J, et al. Influence of oxygen
concentration and pH on expression of hypoxia induced genes.
Radiother Oncol 2005;76:187–93.
[19] Troost EG, Laverman P, Kaanders JH, et al. Imaging
hypoxia after oxygenation-modification: comparing
[18F]FMISO autoradiography with pimonidazole immunohisto-
chemistry in human xenograft tumors. Radiother Oncol
2006;80:157–64.
[20] van ’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression
profiling predicts clinical outcome of breast cancer. Nature
2002;415:530–6.
[21] van de Vijver MJ, He YD, van’t Veer LJ, et al. A
gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med 2002;347:
1999–2009.
[22] Vaupel P. The role of hypoxia-induced factors in tumor
progression. Oncologist 2004;9:10–7.
[23] Wouters BG, van den Beucken T, Magagnin MG, Lambin P,
Koumenis C. Targeting hypoxia tolerance in cancer. Drug
Resist Updat 2004;7:25–40.
